Oral Omadacycline vs. Oral Linezolid for the Treatment of ABSSSI (NCT02877927) | Clinical Trial Compass
CompletedPhase 3
Oral Omadacycline vs. Oral Linezolid for the Treatment of ABSSSI
United States735 participantsStarted 2016-08
Plain-language summary
The purpose of this study is to evaluate the safety and efficacy of omadacycline as compared to linezolid in the treatment of adults with acute bacterial skin and skin structure infections.
Who can participate
Age range18 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Patients, ages 18 years or older who have signed the informed consent
* Has a qualifying skin and skin structure infection
* Female patients must not be pregnant at the time of enrollment
* Must agree to a reliable method of birth control during the study and for 30 days following the last dose of study drug
Exclusion Criteria:
* Infections where the outcome is strongly influenced by factors other than protocol-defined treatments and procedures, or that require antibacterial treatment for greater than 14 days
* Evidence of significant immunological disease
* Severe renal disease or requirement for dialysis
* Evidence of septic shock
* Has a history of hypersensitivity or allergic reaction to any tetracycline or to linezolid
* Has received an investigational drug within the past 30 days
* Women who are pregnant or nursing
What they're measuring
1
Number of Participants With Early Clinical Response
Timeframe: Screening; 48 to 72 hours after the first dose of test article